CN102548556A - 片剂 - Google Patents

片剂 Download PDF

Info

Publication number
CN102548556A
CN102548556A CN2010800431623A CN201080043162A CN102548556A CN 102548556 A CN102548556 A CN 102548556A CN 2010800431623 A CN2010800431623 A CN 2010800431623A CN 201080043162 A CN201080043162 A CN 201080043162A CN 102548556 A CN102548556 A CN 102548556A
Authority
CN
China
Prior art keywords
tablet
weight
chemical compound
salt
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800431623A
Other languages
English (en)
Chinese (zh)
Inventor
村川佑介
冈部贵幸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102548556(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN102548556A publication Critical patent/CN102548556A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800431623A 2009-07-28 2010-07-27 片剂 Pending CN102548556A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-175695 2009-07-28
JP2009175695 2009-07-28
PCT/JP2010/062568 WO2011013639A1 (ja) 2009-07-28 2010-07-27 錠剤

Publications (1)

Publication Number Publication Date
CN102548556A true CN102548556A (zh) 2012-07-04

Family

ID=43529294

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800431623A Pending CN102548556A (zh) 2009-07-28 2010-07-27 片剂

Country Status (23)

Country Link
US (1) US20120129878A1 (enExample)
EP (1) EP2460523B1 (enExample)
JP (1) JP5732394B2 (enExample)
KR (1) KR20120039046A (enExample)
CN (1) CN102548556A (enExample)
AU (1) AU2010279171A1 (enExample)
BR (1) BR112012001959A2 (enExample)
CA (1) CA2769177A1 (enExample)
CL (1) CL2012000182A1 (enExample)
CO (1) CO6612226A2 (enExample)
CR (1) CR20120061A (enExample)
EA (1) EA201270204A1 (enExample)
EC (1) ECSP12011699A (enExample)
IL (1) IL217560A0 (enExample)
IN (1) IN2012DN00954A (enExample)
MA (1) MA33539B1 (enExample)
MX (1) MX2012001284A (enExample)
PE (1) PE20120919A1 (enExample)
SG (1) SG178062A1 (enExample)
TN (1) TN2012000031A1 (enExample)
TW (1) TW201106991A (enExample)
WO (1) WO2011013639A1 (enExample)
ZA (1) ZA201200761B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103877054A (zh) * 2012-12-21 2014-06-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN105596341A (zh) * 2016-03-14 2016-05-25 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
CN109069455A (zh) * 2016-05-10 2018-12-21 日本脏器制药株式会社 对乙酰氨基酚制剂的制造方法
CN116763752A (zh) * 2023-08-24 2023-09-19 北京福元医药股份有限公司 一种阿卡波糖片剂及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
AR092843A1 (es) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co Preparacion solida
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂
CN105078974A (zh) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及药物组合物
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
CN114122219B (zh) * 2020-08-28 2025-04-08 群创光电股份有限公司 发光单元

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09169641A (ja) * 1995-12-20 1997-06-30 Taiyo Yakuhin Kogyo Kk ロキソプロフェン製剤
JP2006070024A (ja) * 2004-08-05 2006-03-16 Meiji Milk Prod Co Ltd 顆粒状製剤及びその製造方法
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
WO2008114800A2 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
PL376733A1 (pl) 2002-11-01 2006-01-09 Takeda Pharmaceutical Company Limited Środek do zapobiegania lub leczenia neuropatii
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
PL1897558T3 (pl) * 2005-06-09 2014-01-31 Norgine Bv Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
CA2617969A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ES2379661T3 (es) 2006-06-27 2012-04-30 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados
MY145447A (en) 2006-09-13 2012-02-15 Takeda Pharmaceutical Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
JP5284967B2 (ja) * 2007-02-01 2013-09-11 武田薬品工業株式会社 打錠障害を生じない錠剤製剤
CA2677736A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US8400391B2 (en) 2008-01-10 2013-03-19 Honeywell International Inc. Method and system for improving dimming performance in a field sequential color display device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09169641A (ja) * 1995-12-20 1997-06-30 Taiyo Yakuhin Kogyo Kk ロキソプロフェン製剤
JP2006070024A (ja) * 2004-08-05 2006-03-16 Meiji Milk Prod Co Ltd 顆粒状製剤及びその製造方法
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
WO2008114800A2 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103877054A (zh) * 2012-12-21 2014-06-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN105596341A (zh) * 2016-03-14 2016-05-25 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
CN109069455A (zh) * 2016-05-10 2018-12-21 日本脏器制药株式会社 对乙酰氨基酚制剂的制造方法
CN109069455B (zh) * 2016-05-10 2020-10-09 日本脏器制药株式会社 对乙酰氨基酚制剂的制造方法
US11033501B2 (en) 2016-05-10 2021-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Method for manufacturing acetaminophen preparation
US11433031B2 (en) 2016-05-10 2022-09-06 Nippon Zoki Pharmaceutical Co., Ltd. Method for manufacturing acetaminophen preparation
CN116763752A (zh) * 2023-08-24 2023-09-19 北京福元医药股份有限公司 一种阿卡波糖片剂及其制备方法
CN116763752B (zh) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 一种阿卡波糖片剂及其制备方法

Also Published As

Publication number Publication date
IN2012DN00954A (enExample) 2015-04-10
CL2012000182A1 (es) 2012-10-12
CR20120061A (es) 2012-03-06
IL217560A0 (en) 2012-02-29
PE20120919A1 (es) 2012-08-13
MA33539B1 (fr) 2012-08-01
CA2769177A1 (en) 2011-02-03
TW201106991A (en) 2011-03-01
SG178062A1 (en) 2012-03-29
AU2010279171A1 (en) 2012-03-01
EA201270204A1 (ru) 2012-08-30
EP2460523A4 (en) 2014-02-26
KR20120039046A (ko) 2012-04-24
TN2012000031A1 (en) 2013-09-19
US20120129878A1 (en) 2012-05-24
ECSP12011699A (es) 2012-03-30
JPWO2011013639A1 (ja) 2013-01-07
JP5732394B2 (ja) 2015-06-10
EP2460523A1 (en) 2012-06-06
WO2011013639A1 (ja) 2011-02-03
BR112012001959A2 (pt) 2016-03-15
MX2012001284A (es) 2012-03-26
ZA201200761B (en) 2013-05-29
CO6612226A2 (es) 2013-02-01
EP2460523B1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
CN102548556A (zh) 片剂
JP5432720B2 (ja) ２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤
US8632808B2 (en) Taste-masking solid preparation of pioglitazone
TWI438201B (zh) 固體製劑
EP2124901A1 (en) Tablet preparation without causing a tableting trouble
TW201350143A (zh) 固體型製劑
WO2014014129A1 (en) Solid preparation
US9757377B2 (en) Solid preparation
HK1171666A (en) Tablet

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120704